Retrospective Study
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Dec 16, 2021; 9(35): 10838-10849
Published online Dec 16, 2021. doi: 10.12998/wjcc.v9.i35.10838
Ninety-four thousand-case retrospective study on antibacterial drug resistance of Helicobacter pylori
Yu Zhang, Fei Meng, Jie Jin, Jun Wang, Bin-Bin Gu, Jin-Bang Peng, Li-Ping Ye
Yu Zhang, Jun Wang, Bin-Bin Gu, Jin-Bang Peng, Li-Ping Ye, Department of Gastroenterology, Taizhou Hospital of Zhejiang Province, Linhai 318000, Zhejiang Province, China
Fei Meng, Jie Jin, Department of Research Service, Zhiyuan Medical Inspection Institute CO., LTD, Hangzhou 310030, Zhejiang Province, China
Li-Ping Ye, Department of Gastroenterology, Taizhou Hospital Affiliated to Wenzhou Medical University, Taizhou 318000, Zhejiang Province, China
Author contributions: Zhang Y and Ye LP formulated the problem; Meng F and Jin J performed the microbial culture and susceptibility testing; Wang J analyzed the data; Gu BB and Peng JB collected samples; Zhang Y and Ye LP wrote the paper; all authors read, reviewed and approved the manuscript.
Supported by Taizhou Science and Technology Plan Project, No. 1701KY20.
Institutional review board statement: The study was reviewed and approved by the ethics committee of Taizhou Hospital of Zhejiang Province.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: All the Authors have no conflict of interest related to the manuscript.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Li-Ping Ye, PhD, Director, Department of Gastroenterology, Taizhou Hospital of Zhejiang Province, No.150 Ximen Street, Linhai 318000, Zhejiang Province, China. 774201768@qq.com
Received: April 22, 2021
Peer-review started: April 22, 2021
First decision: May 24, 2021
Revised: June 1, 2021
Accepted: September 14, 2021
Article in press: September 14, 2021
Published online: December 16, 2021
Processing time: 231 Days and 23.8 Hours
ARTICLE HIGHLIGHTS
Research background

The trend of Helicobacter pylori (H. pylori) prevalence and antibacterial drug resistance is getting more serious.

Research motivation

To provide guidance on the use of antimicrobial drugs for H. pylori eradication treatment based on the trend of antimicrobial resistance.

Research objectives

Big data-based research of H. pylori prevalence and antimicrobial resistance trends in Taizhou, Zhejiang Province were performed.

Research methods

Carried out the statistical analysis of the results of gastric mucosal tissue sample culture and drug susceptibility tests in Taizhou in the past 10 years, and explored the differences between different age groups and gender of the H. pylori prevalence and antibacterial drug resistance rates.

Research results

The prevalence of H. pylori increased with age, and males were at a higher risk of H. pylori prevalence. The resistance rate increased with age, and H. pylori in females, age 21-years-old to 50-years-old, were at a higher risk of resistance to levofloxacin and clarithromycin.

Research conclusions

The prevalence and resistance of H. pylori in Taizhou city are serious.

Research perspectives

Guided by the consensus report, individualized treatment based on an AST is recommended.